Search
for
Sort by
Research 331–360 of 1000+
- Community Detection and Patient Experience Analysis in Reddit Conversations on Janus Kinase Inhibitors using Large Language Models
- BH14 Irish dermatologists’ experience with Janus kinase inhibitors in alopecia areata
- In pemphigus, cell detachment, but not autoantibody binding, induces cell-wide, long-lasting transcriptomic and proteomic changes
- Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: A Retrospective Case Series and Literature Review
- An Overview about Alopecia Areata Etiopathogenesis, Diagnosis, and Management: Review Article
- Updates In The Pathogenesis Of Alopecia Areata
- Tofacitinib citrate alleviates alopecia universalis symptoms in recent case study
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Genes and Immune Response in Alopecia Areata: Review of the Alopecia Areata Research Summit First Day Proceedings
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry
- Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
- Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies
- The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
- Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
- Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata
- Treatment of pediatric alopecia areata: A systematic review
- JAK-inhibitors in dermatology: current evidence and future applications
- Review of treatment for alopecia totalis and alopecia universalis
- Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
- Tofacitinib therapy for children with severe alopecia areata
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?